UNSPSC 51144105: Amfepramone hydrochloride

This classification denotes a cns stimulant and anorexiant with the molecular formula C13H19NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19V2PL39NG, chemically known as 1-propanone, 2-(diethylamino)-1-phenyl- but more generally known as amfepramone hydrochloride, which bears US NIH Compound Identifier 7029. European Medicines Agency schedules Amfepramone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00434MIG.

Most nations, for tariff and trade purposes, schedule amfepramone hydrochloride under HS 29223100. SMILES: CCN(CC)C(C)C(=O)C1CCCCC1.CL.

UNSPSC 51144105 Amfepramone hydrochloride is a Commodity code that in practice covers pharmaceutical products and drug-related supplies procured by state and local health agencies, though recent state and local solicitations tagged to this code show limited activity directly matching the specific drug substance named. The recent opportunities reveal a broader pattern: state and local health departments and cooperative purchasing alliances are buying pharmaceutical products—naloxone, generic multi-source pharmaceuticals, OTC products, and related medical supplies—through competitive processes including IFBs, RFPs, and RFIs. The work involves product sourcing, supply chain management with authorized wholesalers, compliance with cGMP and Drug Supply Chain Security Act requirements, and delivery logistics to state and local facilities. Issuing bodies include county health departments (Seminole County, Florida), state health commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with responses due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors in MMCAP contracts must maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and comply with insurance requirements including commercial general liability of $5,000,000 per occurrence.